Castration-resistant prostate cancer (CRPC) is the most common malignant tumor of the male urinary system. Nanodrug delivery systems (NDDS) have been widely applied in drug delivery for tumor therapy; however, nanotherapeutics encounter various biological barriers that prevent successful accumulation of drugs, specifically at diseased sites. Therefore, there is an urgent need to develop a CRPC-targeting nanocomposite with fine biocompatibility for penetrating various biological barriers, delivering sufficient drugs to the targeting site and improving therapeutic efficiency. In this work, CRPC cell membranes were firstly adapted as biomimetic vectors for the encapsulating PEG−PLGA polymer containing the chemotherapy drug docetaxel (DTX). The CRPC membrane-camouflaged nanoparticles can easily escape early recognition by the immune system, penetrate the extracellular barrier, and evade clearance by the circulatory system. In addition to the characteristics of traditional nanoparticles, the CRPC cell membrane contains an arsenal of highly specific homotypic moieties that can be used to recognize the same cancer cell types and increase the targeted drug delivery of DTX. In vivo fluorescence and radionuclide dual-model imaging were fulfilled by decorating the biomimetic nanosystem with near-infrared dye and isotope, which validated the homotypic targeting property offered by the CRPC cell membrane coating. Importantly, remarkably improved therapeutic efficacy was achieved in a mice model bearing CRPC tumors. This homologous cell membrane enabled an efficient drug delivery strategy and enlightened a new pathway for the clinical application of tumor chemotherapy drugs in the future.
Objective: At present, prostate cancer radical surgery still lacks an objective standard for predicting the anatomic difficulty of surgery through preoperative examination. Due to the poor prognosis and surgical complications caused by "Narrow Pelvis", a pelvic model for prediction is urgently needed. The purpose of this study is to present objective preoperative assessing indicators to predict the surgical difficulty caused by pelvic anatomic abnormalities during laparoscopic radical prostatectomy(LRP). Methods: Patients undergoing LRP were retrospectively analyzed and separated into “Common Pelvis” or “Difficult Pelvis” groups according to the preset criteria. The clinical data and pelvic imaging data of the two groups were compared to obtain statistically significant differences. The results were compared and validated in 500 ordinary males. Logistic regression analysis was performed to optimize these indicators into a scoring model, “Laparoscopic Radical Prostatectomy Narrow Pelvic Predictive Index (LRP-NPPI)” for predicting “Difficult Pelvis”. Results: Of the 145 patients undergoing LRP, 22(15.2%) were included in the “Difficult Pelvis” group. Patients in the “Difficult Pelvis” group were more likely to have a narrower, shorter, deeper, more flattened pelvis, greater BMI, more history of previous pelvic surgery and greater prostate volume. Moreover, the larger amount of intraoperative blood loss and longer operation time were related. Compared with “Common Pelvis” group, patients in the “Difficult Pelvis” have higher score of LRP-NPPI(P<0.05). Conclusion: With the model we proposed, it is possible to predict patients with pelvic anatomical difficulties during laparoscopic radical prostatectomy.